title: Positron emission tomography imaging of pancreatic cancer.
abstract: Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is increasingly used for the staging of solid malignancies, including lung and esophagus. However, controversy still exists in relation to the application of PET in pancreatic cancer. The authors review seven studies (Abstracts #183, #189, #190, #254, #357, #375, #378) presented at the 2014 ASCO Gastrointestinal Cancers Symposium and discuss on the role of PET in this disease. As the limitations of the Response Evaluation Criteria In Solid Tumors (RECIST) continue to become evident, FDG-PET may identify changes in the metabolic activity within pancreatic adenocarcinoma, and can provide both diagnostic and prognostic information.
authors.affiliation: Columbia University Medical Center. New York, NY, USA. sk3552@columbia.edu.
authors.forename: Saravanan Kokila
authors.initials: SK
authors.lastname: Krishnamoorthy
authors.forename: Sachin
authors.initials: S
authors.lastname: Jambawaliker
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods / Q000639:trends*; D011379:Prognosis
chemical_list: D019788:Fluorodeoxyglucose F18